Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > RAF inhibitors
Thursday 4 March 2010
Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth.
ATP-competitive RAF inhibitors inhibit ERK signalling in cells with mutant BRAF, but unexpectedly enhance signalling in cells with wild-type BRAF.
RAF inhibitors do not inhibit ERK signalling in cells that coexpress BRAF-V600E and mutant RAS. (20179705)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. Nature. 2010 Feb 23. PMID: 20179705